132 related articles for article (PubMed ID: 9581987)
1. Effects of interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease.
Mazzoran L; Tamaro G; Mangiarotti MA; Marchi P; Baracetti S; Gerini U; Fanni-Cannelles M; Zorat F; Pozzato G
Eur J Gastroenterol Hepatol; 1998 Feb; 10(2):125-31. PubMed ID: 9581987
[TBL] [Abstract][Full Text] [Related]
2. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
[TBL] [Abstract][Full Text] [Related]
3. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C.
Yamada M; Fukuda Y; Koyama Y; Nakano I; Urano F; Katano Y; Hayakawa T
J Gastroenterol Hepatol; 1996 Jul; 11(7):646-51. PubMed ID: 8840240
[TBL] [Abstract][Full Text] [Related]
4. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha.
Hiramatsu N; Hayashi N; Kasahara A; Hagiwara H; Takehara T; Haruna Y; Naito M; Fusamoto H; Kamada T
J Hepatol; 1995 Feb; 22(2):135-42. PubMed ID: 7790701
[TBL] [Abstract][Full Text] [Related]
5. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C.
Ishibashi K; Kashiwagi T; Ito A; Tanaka Y; Nagasawa M; Toyama T; Ozaki S; Naito M; Azuma M
Hepatology; 1996 Jul; 24(1):27-31. PubMed ID: 8707274
[TBL] [Abstract][Full Text] [Related]
6. Serum markers for hepatic fibrosis in alcoholic liver disease: which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase, or prolyl hydroxylase?
Tsutsumi M; Takase S; Urashima S; Ueshima Y; Kawahara H; Takada A
Alcohol Clin Exp Res; 1996 Dec; 20(9):1512-7. PubMed ID: 8986196
[TBL] [Abstract][Full Text] [Related]
7. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.
Nousbaum JB; Pol S; Nalpas B; Landais P; Berthelot P; Bréchot C
Ann Intern Med; 1995 Feb; 122(3):161-8. PubMed ID: 7810932
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum 7S collagen in various liver diseases.
Yamada S; Suou T; Kawasaki H; Yoshikawa N
Clin Biochem; 1992 Dec; 25(6):467-70. PubMed ID: 1335851
[TBL] [Abstract][Full Text] [Related]
10. alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers.
Capra F; Casaril M; Gabrielli GB; Tognella P; Rizzi A; Dolci L; Colombari R; Mezzelani P; Corrocher R; De Sandre G
J Hepatol; 1993 Apr; 18(1):112-8. PubMed ID: 8340603
[TBL] [Abstract][Full Text] [Related]
11. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.
Hino K; Sainokami S; Shimoda K; Iino S; Wang Y; Okamoto H; Miyakawa Y; Mayumi M
J Med Virol; 1994 Mar; 42(3):299-305. PubMed ID: 7516422
[TBL] [Abstract][Full Text] [Related]
12. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon.
Gallorini A; Plebani M; Pontisso P; Chemello L; Masiero M; Mantovani G; Alberti A
Liver; 1994 Oct; 14(5):257-64. PubMed ID: 7997085
[TBL] [Abstract][Full Text] [Related]
13. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.
Pawlotsky JM; Darthuy F; Rémiré J; Pellet C; Udin L; Stuyver L; Roudot-Thoraval F; Duvoux C; Douvin C; Mallat A
J Med Virol; 1995 Nov; 47(3):285-91. PubMed ID: 8551282
[TBL] [Abstract][Full Text] [Related]
14. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.
Karino Y; Toyota J; Sugawara M; Miyazaki K; Kuwata Y; Yamazaki K; Sato T; Ohmura T; Matsushima T
J Gastroenterol Hepatol; 2003 Apr; 18(4):404-10. PubMed ID: 12653888
[TBL] [Abstract][Full Text] [Related]
16. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.
Lau JY; Davis GL; Kniffen J; Qian KP; Urdea MS; Chan CS; Mizokami M; Neuwald PD; Wilber JC
Lancet; 1993 Jun; 341(8859):1501-4. PubMed ID: 8099380
[TBL] [Abstract][Full Text] [Related]
17. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease.
Yamada M; Fukuda Y; Nakano I; Katano Y; Takamatsu J; Hayakawa T
Acta Haematol; 1998; 99(4):212-6. PubMed ID: 9644299
[TBL] [Abstract][Full Text] [Related]
18. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
19. Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan.
Yoshikawa M; Fukui H; Kojima H; Yoshiji H; Sakamoto T; Imazu H; Nakanani T; Matsumura Y; Kuriyama S; Yamao J
J Gastroenterol; 1995 Jun; 30(3):367-71. PubMed ID: 7647904
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate therapy and liver fibrosis: are human prolyl hydroxylase and type IV collagen reliable and sensitive markers?
Tamaro G; Danek GM; Mangiarotti MA; Tamaro P; Zanazzo GA
Int J Clin Lab Res; 1995; 25(1):55. PubMed ID: 7787212
[No Abstract] [Full Text] [Related]
[Next] [New Search]
